Rapamycin Target Eluting Coronary Stent System
- UID
- IMP/MD/2020/000488_3fba776a36a187f3455d08ebc1c9c9c2_11cce3c17e714d5ee9d14197522c4523
- Device class
- Class D
- Brand name
- FirehawkTM Rapamycin Target Eluting Coronary Stent
- License holder
- Purple MicroPort Cardiovascular Private Limited
- Approving authority
- CDSCO
- Product information
- The Firehawk LibertyTM Rapamycin Target Eluting Coronary Stent System (FirehawkTM Rapamycin Target Eluting Coronary Stent) is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions
Rapamycin Target Eluting Coronary Stent System is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/MD/2020/000488_3fba776a36a187f3455d08ebc1c9c9c2_11cce3c17e714d5ee9d14197522c4523. This device is marketed under the brand name FirehawkTM Rapamycin Target Eluting Coronary Stent. The license holder is Purple MicroPort Cardiovascular Private Limited, and it is classified as Device Class Class D. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.